Enhancing and leveraging principal investigator and patient advocacy group collaboration in rare disease clinical research-meeting report from the rare Diseases Clinical Research Network
Kristen Wheeden(American Occupational Therapy Association), Michael Seid, Mirna Chehade(New York Proton Center), Sheridan N. Meyers(Cincinnati Children's Hospital Medical Center), Rogerwene C. Gifford(Cincinnati Children's Hospital Medical Center), Eileen King(Cincinnati Children's Hospital Medical Center), Kristin Anthony(PTEN Hamartoma Tumor Syndrome Foundation)
Cited by 1
Related Papers
The PedsQL™* 4.0 as a Pediatric Population Health Measure: Feasibility, Reliability, and Validity
|Ambulatory Pediatrics|2003|2.3k
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
|New England Journal of Medicine|2022|452
The Pediatric Cancer Quality of Life Inventory (PCQL). I. Instrument Development, Descriptive Statistics, and Cross-Informant Variance
|Journal of Behavioral Medicine|1998|236
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
|New England Journal of Medicine|2024|107
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2023|100